Harvard’s ARMMs technology to be commercialized by Vesigen Therapeutics for targeted intracellular delivery of large-molecule drugs

Five Fellows will work with innovators across Harvard community, advance commercialization of life-science technologies

New formulations enable oral delivery of therapeutics traditionally delivered intravenously

Genetically programmed, living hydrogel material facilitates intestinal wound healing and may lead to a therapy for patients with inflammatory bowel disease